Sven Ante Lundberg

Insider Reports History

Entity
Individual
Location
C/O Crispr Therapeutics Ag, 200 Sidney Street, Cambridge, MA
Signature
/s/ Katie Kazem, Attorney-in-Fact
All insider transactions
Transactions in reports broken out by “transaction date” reported in original SEC filing, see here for transactions aggregated across transaction date

Holdings reported by Sven Ante Lundberg:

Stock Role Class Num Shares Value Price $ Report Date Ownership
Merus N.V. President, CEO & PEO, Director Share Option (right to buy) 360K $4.87M $13.52 May 7, 2024 Direct
Homology Medicines, Inc. Director Stock Option (Right to Buy) 12.8K $171K $13.42 Mar 25, 2024 Direct
Homology Medicines, Inc. Director Common Stock 1.2K $685 $0.57 Mar 25, 2024 Direct
Vor Biopharma Inc. Director Stock Option (Right to Buy) 30K May 23, 2024 Direct

Insider Reports Filed by Sven Ante Lundberg

Symbol Company Period Transactions Value $ Form Type Date Filed Role
VOR Vor Biopharma Inc. May 23, 2024 1 $0 4 May 28, 2024 Director
MRUS Merus N.V. May 7, 2024 1 $0 4 May 9, 2024 President, CEO & PEO, Director
QTTB Homology Medicines, Inc. Mar 25, 2024 1 $0 4 Mar 27, 2024 Director
QTTB Homology Medicines, Inc. Mar 25, 2024 0 $0 3 Mar 27, 2024 Director
VOR Vor Biopharma Inc. May 26, 2023 1 $0 4 Jun 2, 2023 Director
MRUS Merus N.V. Feb 2, 2023 1 $0 4 Feb 3, 2023 President, CEO & PFO, Director
MRUS Merus N.V. Nov 3, 2022 1 $211K 4 Nov 3, 2022 President, CEO & PFO, Director
MRUS Merus N.V. Aug 22, 2022 0 $0 4/A Oct 24, 2022 President, CEO & PFO, Director
MRUS Merus N.V. Aug 19, 2022 1 $16.2K 4 Aug 22, 2022 President, CEO & PFO, Director
MRUS Merus N.V. Jul 12, 2022 1 $99.7K 4 Jul 13, 2022 President, CEO & PFO, Director
VOR Vor Biopharma Inc. Jun 14, 2022 1 $0 4 Jun 16, 2022 Director
MRUS Merus N.V. Jan 31, 2022 1 $0 4 Feb 2, 2022 President, CEO & PFO, Director
MRUS Merus N.V. Aug 2, 2021 4 $0 4 Aug 4, 2021 President, CEO & PFO, Director